Zeneca Limited

Medimmune Limited

Astrazeneca Ab

Medlmmune Limited

David Charles Blakey

Stephen Charles Emery

Larry L Green

Bruce Alan Keyt

Xiao-Dong Yang

Qing Zhou

Ian Nevin Foltz

Jaspal Singh Kang

Francis Thomas Boyle

David Huw Davies

Peter R Marsham

Gadi Gazit-Bornstein

Naomi Laing

Anthony Michael Slater

Sue Ann Cartlidge

Xiao-Dang Yang

John Frederick Hennam

Laurent Francois Andre Hennequin

Robert I Dowell

Jean-Claude Arnould

David William Heaton

Laurent Francois Hennequin

Clive Graham Copley

Thomas Geoffrey Bird

Brian Robert Rabin

Christopher John Taylorson

Hendrikus Johannes Eggelte

Antonio Tarragona-Fiol

Andrew Firman Wright

Susan Margaret Hall

Michael Samuel Rose

Douglas Stephen Paterson

Christopher Boot

Jeffrey Lester Brown

Xiaodong Intradigm Corporation Yang

Laura Taylor

Susan Ann Cartlidge

Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Antibodies directed to angiopoietin-2 and uses thereof

Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

Targeted binding agents directed to PDGRF-alpha and uses thereof

Targeted binding agents directed to PDGFR-alpha and uses thereof

The invention provides a compound of Formula (I).Wherein R1, R2, R3, R10 and R11 have the meanings given in the description. Such compounds are predicted to cause the selective destruction of tumour vasculature. They may therefore be used to inhibit and/or reverse, and/or alleviate symptoms of angiogenesis and/or any disease state associated with angiogenesis.

Indole derivatives with vascular damaging activity

Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.

Chemical compounds

The invention provides a gene construct encoding a cell targeting moiety and a heterologous prodrug activating enzyme for use as a medicament in a mammalian host wherein the gene construct is capable of expressing the cell targeting moiety and enzyme as a conjugate within a target cell in the mammalian host and wherein the conjugate is directed to leave the cell thereafter for selective localisation at a cell surface antigen recognised by the cell targeting moiety.

Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety

Antibodies which recognize a tumor related antigen designated CA55.1 such as hybridoma 55.1 deposited as ECACC deposit no. 93081901 in which the complementarity determining regions have the following sequences:

Antibodies recognizing tumor associated antigen CA 55.1

Growing community of inventors

Macclesfield, United Kingdom

David Charles Blakey